End-of-day quote
Korea S.E.
03:30:00 03/07/2024 am IST
|
5-day change
|
1st Jan Change
|
2,640
KRW
|
-6.55%
|
|
-0.94%
|
-9.43%
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
43,595
|
42,348
|
1,57,216
|
77,460
|
64,358
|
54,471
|
Enterprise Value (EV)
1 |
41,459
|
45,594
|
1,22,781
|
55,547
|
59,660
|
52,226
|
P/E ratio
|
-11.6
x
|
-3.2
x
|
-9.54
x
|
-15.2
x
|
-8.18
x
|
-9.01
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
2.93
x
|
2.72
x
|
10.3
x
|
3.37
x
|
3.79
x
|
2.48
x
|
EV / Revenue
|
2.79
x
|
2.93
x
|
8.03
x
|
2.42
x
|
3.51
x
|
2.38
x
|
EV / EBITDA
|
-34.3
x
|
-7.29
x
|
-31.8
x
|
-13.1
x
|
-17.4
x
|
-19.3
x
|
EV / FCF
|
-28.2
x
|
-11.8
x
|
233
x
|
-5.56
x
|
-19.9
x
|
-8.89
x
|
FCF Yield
|
-3.54%
|
-8.46%
|
0.43%
|
-18%
|
-5.03%
|
-11.2%
|
Price to Book
|
2.22
x
|
4.38
x
|
4.06
x
|
2.36
x
|
2.31
x
|
2.07
x
|
Nbr of stocks (in thousands)
|
10,738
|
11,477
|
16,394
|
16,394
|
17,094
|
18,687
|
Reference price
2 |
4,060
|
3,690
|
9,590
|
4,725
|
3,765
|
2,915
|
Announcement Date
|
20/03/19
|
19/03/20
|
23/03/21
|
21/03/22
|
30/03/23
|
20/03/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
1 |
14,876
|
15,573
|
15,286
|
22,992
|
16,981
|
21,949
|
EBITDA
1 |
-1,208
|
-6,257
|
-3,867
|
-4,230
|
-3,438
|
-2,707
|
EBIT
1 |
-2,923
|
-8,386
|
-6,004
|
-5,920
|
-5,330
|
-4,235
|
Operating Margin
|
-19.65%
|
-53.85%
|
-39.28%
|
-25.75%
|
-31.39%
|
-19.29%
|
Earnings before Tax (EBT)
1 |
-3,753
|
-13,137
|
-13,773
|
-6,191
|
-8,077
|
-5,596
|
Net income
1 |
-3,753
|
-13,118
|
-13,067
|
-5,100
|
-7,782
|
-5,596
|
Net margin
|
-25.23%
|
-84.24%
|
-85.48%
|
-22.18%
|
-45.82%
|
-25.5%
|
EPS
2 |
-349.5
|
-1,151
|
-1,005
|
-311.1
|
-460.0
|
-323.4
|
Free Cash Flow
1 |
-1,469
|
-3,858
|
527.9
|
-9,998
|
-3,002
|
-5,873
|
FCF margin
|
-9.87%
|
-24.77%
|
3.45%
|
-43.49%
|
-17.68%
|
-26.76%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
20/03/19
|
19/03/20
|
23/03/21
|
21/03/22
|
30/03/23
|
20/03/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
-
|
3,245
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
2,136
|
-
|
34,435
|
21,913
|
4,697
|
2,245
|
Leverage (Debt/EBITDA)
|
-
|
-0.5187
x
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-1,469
|
-3,858
|
528
|
-9,998
|
-3,002
|
-5,873
|
ROE (net income / shareholders' equity)
|
-17.4%
|
-89.6%
|
-58.4%
|
-18.3%
|
-27.7%
|
-20.7%
|
ROA (Net income/ Total Assets)
|
-6.08%
|
-17.2%
|
-9.57%
|
-7.91%
|
-7.88%
|
-6.43%
|
Assets
1 |
61,766
|
76,299
|
1,36,579
|
64,480
|
98,716
|
86,970
|
Book Value Per Share
2 |
1,826
|
842.0
|
2,361
|
1,999
|
1,632
|
1,406
|
Cash Flow per Share
2 |
1,100
|
557.0
|
2,254
|
358.0
|
628.0
|
351.0
|
Capex
1 |
2,515
|
2,576
|
1,098
|
4,020
|
4,932
|
2,876
|
Capex / Sales
|
16.9%
|
16.54%
|
7.18%
|
17.48%
|
29.04%
|
13.1%
|
Announcement Date
|
20/03/19
|
19/03/20
|
23/03/21
|
21/03/22
|
30/03/23
|
20/03/24
|
|
1st Jan change
|
Capi.
|
---|
| -9.43% | 38.1M | | +16.59% | 44.87B | | -10.62% | 37.8B | | +40.49% | 37.61B | | +29.92% | 31.32B | | -9.78% | 27.4B | | +12.34% | 26.32B | | +41.53% | 14.07B | | +31.49% | 12.5B | | -7.40% | 11.23B |
Other Biotechnology & Medical Research
|